Trials / Completed
CompletedNCT04271514
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Multiple-dose Escalation, and Food Effect Study of RPT193 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- RAPT Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and selective antagonist of CCR4.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RPT193 | Antagonist of the CCR4 chemokine receptor |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2019-08-12
- Primary completion
- 2021-04-26
- Completion
- 2021-04-26
- First posted
- 2020-02-17
- Last updated
- 2021-09-30
Locations
14 sites across 2 countries: United States, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04271514. Inclusion in this directory is not an endorsement.